Interleukin (IL)-8 production by human polymorphonuclear leukocytes (PMNL) to
neoformans infection is poorly understood, one can anticipate that the paucity of CD4 T cells in persons with AIDS contributes to their marked predisposition for disseminated infection. Because PMNL are potent anticryptococcal cells and persons with AIDS have normal numbers of PMNL, it is possible that they counterbalance CD4 cell impairment and protect against C. neoformans. However, the functional status of PMNL may be compromised in human immunodeficiency virus (HIV)-positive persons. HIV-infected persons have reduced chemotaxis for PMNL [10] but preserved fungicidal mechanisms [11, 12] .
The complex biology of PMNL involves the ability to sense chemotactic factors and to migrate, perform phagocytosis, and kill microbes. In recent years, several researchers have firmly established that the release of cytokines constitutes an important aspect of neutrophil biology [13] . Such cytokines as tumor necrosis factor-a, interferon (IFN)-a, macrophage-CSF, G-CSF, interleukin (IL)-1, IL-1 receptor antagonist, IL-6, and IL-8 are produced by PMNL [14] [15] [16] . IL-8, a small protein that is a member of a supergene family of chemotactic cytokines produced by PMNL, is important in promoting inflammatory responses. Biologic actions of IL-8 on neutrophils include the induction of respiratory burst and chemotaxis [17] [18] [19] , promoting release of lysosomal enzymes, and enhanced killing of various microorganisms, including Mycobacterium tuberculosis [20] .
We previously demonstrated that PMNL from normal persons release IL-8 in response to C. neoformans or capsular material, glucuronoxylomannan. This effect is related to acti-vation of the complement system and release of biologically active complement cleavage fragments, such as C3a and C5a, that are involved in the induction of IL-8 release. C5a is also involved in the induction of protective immune response to C. neoformans [21] .
Although many studies have assessed neutrophil function in patients with AIDS [10, [22] [23] [24] [25] [26] [27] , studies focusing on PMNL cytokines are scarce [28, 29] . The aim of this study was to determine the production of IL-8 by PMNL from patients with late-stage HIV infection in response to C. neoformans and to explore the mechanisms involved in this phenomenon. In particular, we studied the effect of monoclonal antibody (MAb) 18B7 to the capsular polysaccharide in regulating PMNL functions. This MAb is in advanced preclinical development for use in persons with cryptococcosis [30] . At the time of the study, no patients were receiving cytokine therapy.
Materials and Methods

Subjects
Reagents and media. RPMI 1640 with glutamine and fetal calf serum were obtained from Gibco BRL (Paisley, UK). Human serum (HS) type AB, fluorescein isothiocyanate (FITC)-conjugated MAb anti-rabbit immunoglobulin (mouse IgG1 isotype), FITCconjugated sheep anti-mouse IgG (whole molecule), FITC-conjugated anti-mouse isotype control IgG1, FITC-conjugated anti-rabbit isotype control IgG, and mouse isotype control IgG1,k were purchased from Sigma (St. Louis). Mouse anti-human CD16 MAb (IgG1) was provided by Ancell (Bayport, ME). Mouse anti-human CR3 MAb (IgG1; CD11b/CD18) was obtained from Monosan (Uden, The Netherlands). Rabbit anti-human CD88 (C5aR) MAb (IgG1) was provided by Serotec (Oxford, UK).
The characteristics of MAb 18B7 have been described [30] . MAb 18B7 was purified by protein G affinity chromatography (Pierce, Rockford, IL). The concentration of MAb 18B7 was determined by ELISA relative to isotype-matched standards of known concentrations. Human complement C3a (Cortex Biochem, San Leandro, CA), human complement recombinant C5a (Fluka Chimica, Sigma Aldrich, Milan, Italy), MAb anti-human C3a (Quidel, San Diego), and goat anti-human C5 (Quidel) were purchased. Polyclonal anti-human C5 shows strong reactivity to human C5a [31] . Monoiodoacetic acid (MIA) was purchased from Sigma. All reagents and media used in this study were negative for endotoxin as detected by Limulus amebocyte lysate assay (Sigma), which had a sensitivity of ∼0.05-0.1 ng/mL of Escherichia coli lipopolysaccharide.
Microorganisms. Candida albicans (strain PCA-2) was supplied by D. Kerridge (Department of Biochemistry, University of Cambridge, UK). This is an agerminative strain that grows as a pure yeast form in vitro at 28ЊC or 37ЊC in conventional media. The 2 strains of C. neoformans used in this study were obtained from J. Orendi (Central Bureau Schimmel Cultures [CBS], Delft, The Netherlands). C. neoformans var. neoformans 6995 (CBS 6995; also known as NIH 37) is a thinly encapsulated isolate of serotype A. C. neoformans var. neoformans 7698 (CBS 7698; also known as NIH B-4131) is an acapsular mutant. The morphologic characteristics and conditions for growth of the 2 strains of C. neoformans and the C. albicans isolate have been described elsewhere [32, 33] . The cultures were maintained by serial passage on Sabouraud agar (BioMérieux, Lyon, France) and harvested by suspending a single colony in RPMI 1640. C. neoformans 6995 and 7698 and C. albicans were killed by autoclaving.
Preparation of PMNL.
Heparinized venous blood from healthy donors or from patients with late-stage HIV infection was diluted with RPMI 1640, and mononuclear cells were separated by ficoll-hypaque density gradient centrifugation [34] . The pellet containing PMNL and erythrocytes was treated with hypotonic saline to lyse the erythrocytes. Granulocytes were collected by centrifugation, washed twice in RPMI 1640, counted, and adjusted to the desired concentration. The purity of PMNL isolated by this method was always198%, as determined by Giemsa staining. PMNL preparations contained ∼0.5%-1% eosinophils. PMNL viability, evaluated after 18 h of incubation, was 198% in all determinations by a trypan blue dye exclusion test.
Killing activity against C. albicans or C. neoformans (7698 or 6995). Killing activity was evaluated by colony-forming unit inhibition assay. In brief, PMNL (10 5 ) in 0.1 mL of suspension/ well were incubated in flat-bottom 96-well microtiter tissue culture plates (Falcon, Oxnard, CA) with 10 4 C. albicans or C. neoformans (7698 or 6995) in 0.1 mL of RPMI plus 10% HS in the presence or absence of MAb 18B7 (10 mg/mL) or mouse isotype control IgG1 (10 mg/mL). Cells mixed with C. neoformans were incubated for 2 h. After incubation at 37ЊC with 5% CO 2 , plates were vigorously shaken, cells were lysed by addition of Triton X-100 0.1% in distilled water (final concentration in the well, 0.01%), and serial dilutions were prepared in distilled water. Cell lysates (triplicate samples) were plated for cfu on Sabouraud dextrose agar. After incubation for 24 h at 37ЊC, we counted C. albicans colony-forming units. C. neoformans colony-forming units were counted after a 72-h incubation at 28ЊC. Colony-forming units in experimental wells were compared with colony-forming units for C. albicans or C. neoformans suspensions in RPMI 1640 plus 10% HS without effector cells. Killing activity against C. albicans or C. neoformans was expressed as the percentage of colony-forming unit inhibition by the following formula: % killing activity = [100 Ϫ (colonyforming units from experimental group/colony-forming units from control cultures)] ϫ 100.
Production of PMNL culture supernatants. Isolated PMNL were distributed in 0.1-mL volumes into 96-well U-bottom tissue culture plates (Becton Dickinson, Oxnard, CA) at 4 ϫ 10 6 cells/ mL and incubated for 18 h at 37ЊC in a 5% CO 2 atmosphere with RPMI containing 10% HS with different stimuli. Supernatant fluids were harvested at the indicated times and stored at Ϫ20ЊC until use.
Cytokine level determination. Cytokine levels in culture supernatant fluids were measured by an ELISA kit for human IL-8 (Euroclone, Devon, UK).
Determination of surface expression of CD16, CR3, and CD88 molecules. Freshly isolated human PMNL were analyzed for CD16, CR3, and CD88 surface expression. PMNL (10 6 ) were fixed with 2% paraformaldehyde in PBS for 10 min at room temperature, washed twice in PBS containing 0.5% bovine serum albumin (BSA) and 0.1% sodium azide, and mixed with MAb anti-human CD16 (5 mg/mL), MAb anti-human CR3 (dilution 1/5), or MAb antihuman CD88 (dilution 1/100). After 30 min of incubation on ice, the cells were washed twice and stained with FITC-conjugated sheep anti-mouse IgG (dilution 1/256) for 30 min or FITC-conjugated anti-rabbit immunoglobulin (IgG1). We used irrelevant FITC-conjugated antibodies as negative controls (isotype control, anti-mouse and anti-rabbit IgG, both diluted 1 : 256). CD16, CR3, and CD88 surface expression was measured by flow cytometry (FACScan; Becton Dickinson, Mountain View, CA). Autofluorescence was assessed using untreated cells.
Preparation of fluorescein-labeled C5a. A fluorescence derivate of human C5a (FI-C5a) was prepared with a fluorescein labeling kit (Boehringer Mannheim Biochimica, Mannheim, Germany).
Binding of FI-C5a to PMNL. The binding interaction of FIC5a with human PMNL C5a receptor was defined by accepted methods [35] . In brief, freshly isolated human PMNL were incubated with FI-C5a (25 nM) for 20 min at room temperature. Cells were washed twice in PBS containing 0.5% BSA and 0.1% sodium azide and resuspended in 0.5 mL of PBS containing 0.5% BSA and 0.1% sodium azide. The binding of FI-C5a was assessed by flow cytometry.
Statistical analysis. Statistical analysis was performed by use of Student's t test.
Results
IL-8, a cytokine involved in the inflammatory process, serves as a chemotactic factor to recruit immune cells to the site of infection. Our first series of experiments studied IL-8 release from PMNL of HIV-infected patients in response to C. neoformans. We enrolled 2 patient groups: persons with early-stage HIV infection (1400 CD4 cells/mm 3 ) and patients with latestage HIV infection at high risk for cryptococcosis (!200 CD4 cells/mm 3 ). We recently demonstrated that IL-8 release from normal PMNL coincubated with C. neoformans results from C3a and C5a activation of the complement system by the fungal capsule [8] . Here we extended our study to PMNL from persons with early-and late-stage HIV infection and investigated the mechanism by which MAb 18B7 enhances IL-8 secretion.
PMNL from HIV-positive subjects showed a pattern of IL-8 release similar to that observed for PMNL from normal subjects. The addition of MAb 18B7 induced a significant increase of IL-8 in strain 6995-treated PMNL (figure 1). IL-8 release from PMNL of patients with late-stage HIV infection upon stimulation with encapsulated strain (6995) was rare. However, a significant increase of IL-8 secretion was observed using MAb 18B7 in combination with 6995 (figure 2).
Given that PMNL from patients with late-stage HIV infection are poor producers of IL-8 in response to encapsulated C. neoformans, we considered the possibility of a defect involving unresponsiveness to complement fractions. To test this possibility, we added MAb to C3a and polyclonal antibody to C5a separately to suspensions of C. neoformans and PMNL and measured IL-8 production. As expected, addition of antibody to C3a and C5a produced a significant reduction in IL-8 secretion by PMNL from healthy donors incubated with the encapsulated strain (6995), regardless of the presence or absence of MAb 18B7. In contrast, antibody to C3a and C5a had little or no effect on IL-8 production by PMNL from patients with late-stage HIV infection (figure 3), suggesting that the reduced ability of these cells to secrete IL-8 after exposure to C. neoformans was related to unresponsiveness to C3a or C5a stimulation. Consistent with this hypothesis, addition of purified C3a and C5a to PMNL from persons with late-stage HIV infection resulted in little or no IL-8 production ( figure 3) .
Having established that PMNL from subjects with late-stage HIV infection are poor responders to active complement fractions, we considered the possibility that phagocytosis could be an alternative or adjunctive mechanism for PMNL IL-8 pro- duction. To test this hypothesis, we used MIA, a well-known inhibitor of phagocytosis [36] , in our experiments. Figure 4 shows that appreciable levels of IL-8, produced in response to acapsular C. neoformans and to the encapsulated strain plus MAb 18B7, were abrogated by using MIA (500 nM), suggesting that the preserved phagocytic activity of PMNL may be important for the induction of appreciable levels of IL-8 in the absence of C3a or C5a responsiveness. The importance of the phagocytic process to mediate secretory activity by PMNL was confirmed using opsonized zymosan that was able to induce detectable levels of IL-8 ( figure 5 ). These results indicate that IL-8 production by PMNL from persons with advanced HIV infection can be restored by Fcg receptor activation and phagocytosis.
To study the effect of MAb 18B7-induced phagocytosis in enhancing the functional status of PMNL from persons with late-stage HIV infection, PMNL killing activity against C. neoformans was determined in the presence and absence of MAb 18B7. We recently reported that MAb 18B7 enhances anticryptococcal capacity of PMNL from HIV-infected persons [34] . In the present study, we show that MAb 18B7, by promoting the phagocytic process, augments killing capability of PMNL from patients with late-stage HIV infection.
In contrast to PMNL from persons with early-stage HIV infection, PMNL from those with late-stage infection had reduced antifungal activity against the encapsulated C. neoformans strain. Of interest, PMNL from patients with late-stage HIV infection retained killing activity against C. albicans and the acapsular C. neoformans strain (table 1) . However, addition of MAb 18B7 restored the antifungal activity of PMNL from each of 8 patients with late-stage HIV infection against encapsulated C. neoformans (table 1) . Because PMNL from persons with late-stage HIV infection exhibited deficits in secretory activity despite maintaining phagocytic capacity, we investigated the expression of surface molecules involved in the phagocytic process. Analysis of several important molecules for phagocytosis revealed that CR3 expression (CD11b/CD18) and FcgRIII (CD16) in PMNL from persons with late-stage HIV infection and controls were similar (figure 6). However, the deficit in IL-8 production by PMNL of patients with late-stage HIV infection in response to C3a and C5a stimulation suggested defective expression in the molecules responsible for C5a ligation and expression. To test this hypothesis, we measured CD88 expression on PMNL from patients with late-stage HIV infection and found it was significantly lower than in controls (figure 6). To investigate whether C5a ligation was impaired in PMNL from patients with late-stage HIV infection, C5a FITC conjugate was added, and flow cytometry was done. We found that the reduced expression of CD88 was strictly correlated with impairment of C5a ligation (data not shown).
Discussion
PMNL are the first cells recruited to sites of infection, and their functional status is critical in containing infections. PMNL possess effector and secretory functions and play a critical role in the early response against microbial infections. There is an emerging consensus that PMNL function is preserved during the early stages of AIDS. PMNL integrity, despite severe immune impairment in persons with late-stage HIV infection, may provide the major line of defense against some opportunistic infections (e.g., systemic C. albicans). This suggests the possibility that PMNL may be useful in containing other opportunistic infections, provided that they could be recruited. We previously demonstrated that IL-8 production of PMNL in response to C. neoformans is dependent on the generation of C3a and C5a. Here we extend those studies to compare the antifungal function of PMNL from normal persons with that of PMNL from persons with early and late HIV infection in the presence and absence of specific antibody.
PMNL from persons with early-stage HIV infection secrete IL-8 at levels similar to those of normal subjects in response to C. neoformans. As expected from prior results, the encapsulated strain stimulated more IL-8 production than the acapsular strain, and addition of MAb 18B7 produced a modest, but significant, increase in IL-8 production. In contrast, PMNL from persons with late-stage HIV infection produced significantly less IL-8 after exposure to C. neoformans. PMNL from persons with late-stage HIV infection did not secrete IL-8 in response to direct stimulation with purified C3a and C5a. In contrast, addition of MAb 18B7 to suspensions of PMNL from persons with late-stage HIV infection resulted in a significant increase in IL-8 production. This suggests that PMNL from persons with late-stage HIV infection had preserved responsiveness through Fc receptors but not complement receptors.
Several studies have investigated the mechanism responsible for the differences in IL-8 secretion by PMNL from persons with early-and late-stage HIV infection [28, 37] . Flow cytometry revealed comparable expression of CR3 and FcgRIII receptors in PMNL from the 3 subject groups. However, there was a marked reduction in CD88 expression on PMNL from patients with late-stage HIV infection, suggesting an explanation for the reduced IL-8 secretion based on lower CD88 expression. The fact that MAb 18B7 enhanced IL-8 production from PMNL of persons with late-stage HIV infection suggests cytokine release in response to the phagocytic process. Consis- tent with this explanation, we demonstrated that addition of MIA, a potent inhibitor of phagocytosis, impaired IL-8 release.
Thus, phagocytosis appears to be an alternative or adjunctive mechanism to facilitate IL-8 expression in PMNL and may be the major stimulus for IL-8 release in PMNL from persons with advanced HIV infection.
This study found that PMNL from persons with late-stage HIV infection displayed antifungal activity to acapsular C. neoformans and C. albicans that was comparable to that of PMNL from healthy donors. In contrast, PMNL from persons with late-stage HIV infection were severely impaired in killing encapsulated C. neoformans until MAb 18B7 was added. These results differ slightly from our previous observations that showed a reduced capability of PMNL from patients with latestage HIV infection to kill C. albicans or acapsular C. neoformans [25] . This discrepancy may be due to differences in the donor subjects. Also, the prior study used PMNL from neutropenic patients [25] . The ability of MAb 18B7 to restore killing to encapsulated C. neoformans is consistent with the preserved integrity of Fc receptors in PMNL from patients with late-stage HIV infection. Our results showing intact expression of FcgIII receptors on PMNL and maintenance of their function provide support for potential immunotherapeutic interventions to enhance PMNL function against C. neoformans.
In addition to enhanced PMNL antimicrobial function, MAb 18B7 also enhanced IL-8 release. The effect was significantly greater for PMNL from patients with late-stage HIV infection than for normal PMNL or PMNL from persons with earlystage infection. Presumably, Fc receptor cross-linking is a minor pathway for IL-8 release in the setting of normal complement receptor expression in PMNL. However, in subjects with latestage HIV infection, Fc receptor cross-linking may be a major signal for IL-8 secretion, given the reduced expression of CD88.
The principal activators of IL-8 release remain active complement fragments such as C3a and C5a, as previously observed in PMNL from healthy donors [8] . Of interest, CD88 has a major role in supporting PMNL function, including cytokine release [38] , with respect to C3a. The presence of C3a receptors on PMNL is controversial. Some studies reported the presence of C3a receptors on PMNL [39] ; others suggest that PMNL C3a-mediated activation is subsequent to activation of contaminating eosinophils that bind C3a and release PMNL activating factors [40] . However, there is general consensus on the involvement of CD88 perturbation in regulating a variety of PMNL functions [38, 41, 42] . These effects include promotion of neutrophil chemotaxis [43, 44] , superoxide formation [45] , enzyme release [46] , and cellular aggregation [47] . The consistent impairment of CD88 observed in PMNL from persons with late-stage HIV infection at high risk for cryptococcosis supports our hypothesis that PMNL are unable to respond to C5a-mediated stimuli. It is conceivable that the impairment of additional functions (e.g., chemotaxis) could be ascribed to CD88 impairment. It was recently shown that the copresence of immune complexes and C5a greatly increase chemokine generation in vitro [48] . Similarly, MAb 18B7 could augment IL-8 release through immunocomplex formation. This is consistent with the inability of MAb 18B7 to induce IL-8 release when used in combination with the acapsular strain.
There is convincing evidence for the ability of IFN-g to upregulate CD88 on phagocytic cells [49] , raising the possibility that CD88 defect could be exacerbated in patients with latestage HIV infection (!200 CD4 cells) because of the dramatic impairment of IFN-g production. It would be of interest to verify whether CD88 on PMNL from patients with late HIV infection could be up-regulated by exogenous stimuli and whether restoration of C5a-related functions, such as cytokine production, is also possible.
Overall, our results show that PMNL from persons with late- stage HIV infection have selected impairment of effector function against encapsulated C. neoformans but not against C. albicans or acapsular C. neoformans. Down-regulation of effector function is accompanied by impaired secretory function, likely ascribed to a selective defect of CD88 expression on PMNL. In contrast, the integrity of Fcg receptors ensures multiple beneficial effects of MAb 18B7 in restoring killing capability as well as cytokine production. Pharmacoimmunologic intervention to stimulate expression of CD88 could improve migration of PMNL to the site of infection and promote the inflammatory process, which appears to be rare in patients with late-stage HIV infection.
